All In Biotech

Drug Trial Radar · NCT07390747

A Trial of SHR-2173 in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single Subcutaneous Administration of SHR-2173 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Mar 6, 2026

Primary completion

May 22, 2026

Study completion Sep 28, 2026

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants

Conditions

  • Immunology

Interventions

  • SHR-2173 Injection/SHR-2173 placeboDrug

    Single dose SHR-2173 injection or matching placebo given subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics - CmaxTime frame: Day 71
  2. Pharmacokinetics - AUC₀-tTime frame: Day 71
  3. Pharmacokinetics - AUC₀-infTime frame: Day 71
  4. Pharmacokinetics - TmaxTime frame: Day 71
  5. Pharmacokinetics - t½Time frame: Day 71
  6. Immunogenicity - Anti-Drug Antibody (ADA)Time frame: Day 71

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Veritus Research

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.